Literature DB >> 10588823

Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer.

M R Castro1, E R Bergert, T G Beito, P C Roche, S C Ziesmer, S M Jhiang, J R Goellner, J C Morris.   

Abstract

The recent cloning of the thyroidal protein that is responsible for iodide transport, the sodium iodide symporter (hNIS), has made possible studies designed to characterize its structure, function and expression in thyroidal tissues. Using a mannose binding protein (MBP)-hNIS fusion protein as antigen, we have developed mouse monoclonal antibodies against hNIS to utilize as tools in such studies. Twenty-four clones were initially recovered which recognized the MBP-hNIS fusion protein, but only two of them were specific for hNIS while the others recognized MBP alone. Both antibodies were found to be immunoglobulin G (IgG) 1kappa (kappa). The specificity of antibodies was tested by Western blotting using membranes prepared from COS-7 cells transiently transfected with the pcDNA3 plasmid containing the full-length hNIS cDNA, or cells transfected with the pcDNA3 vector. A major band with a molecular weight (MW) of approximately 97 kDa, and several minor bands with MW of approximately 160 kDa, approximately 68 kDa, approximately 30 kDa and approximately 15 kDa, were detected specifically in the hNIS-transfected cells. After enzymatic deglycosylation, the major band was present at 68 kDa, as expected based upon the amino acid sequence of hNIS. Immunohistochemistry was performed with several different types of thyroid tissue and non-thyroidal tissues, using the monoclonal antibodies. Strong immunostaining was observed in Graves' tissue, with intermediate staining in papillary and follicular thyroid cancers and an absence of staining in Hürthle cell cancer. The staining was specific for the follicular epithelium and was concentrated in the basolateral portion of the cell membrane. These monoclonal hNIS antibodies should prove useful in the characterization of NIS expression in benign and malignant thyroid tissue and in studies characterizing its structure and function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588823     DOI: 10.1677/joe.0.1630495

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  13 in total

1.  A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling.

Authors:  Fang Feng; Lamis Yehia; Ying Ni; Yi Seok Chang; Sissy Meihua Jhiang; Charis Eng
Journal:  Cancer Res       Date:  2018-09-14       Impact factor: 12.701

2.  Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery.

Authors:  Kathrin Klutz; Michael J Willhauck; Nathalie Wunderlich; Christian Zach; Martina Anton; Reingard Senekowitsch-Schmidtke; Burkhard Göke; Christine Spitzweg
Journal:  Hum Gene Ther       Date:  2011-06-28       Impact factor: 5.695

3.  Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line.

Authors:  T Kogai; J J Schultz; L S Johnson; M Huang; G A Brent
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma.

Authors:  Songfeng Wei; Ming Gao; Cui Zhao; Yi Pan; Haixin Li; Jian Li; Xiaolong Li
Journal:  Int J Clin Oncol       Date:  2013-10-05       Impact factor: 3.402

Review 5.  [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].

Authors:  C Spitzweg
Journal:  Internist (Berl)       Date:  2003-04       Impact factor: 0.743

6.  A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.

Authors:  Vicki E Smith; Martin L Read; Andrew S Turnell; Rachel J Watkins; John C Watkinson; Greg D Lewy; Jim C W Fong; Sally R James; Margaret C Eggo; Kristien Boelaert; Jayne A Franklyn; Christopher J McCabe
Journal:  J Cell Sci       Date:  2009-08-25       Impact factor: 5.285

7.  Transcellular thiocyanate transport by human airway epithelia.

Authors:  Miryam A Fragoso; Vania Fernandez; Rosanna Forteza; Scott H Randell; Matthias Salathe; Gregory E Conner
Journal:  J Physiol       Date:  2004-09-02       Impact factor: 5.182

8.  Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?

Authors:  S J Beyer; R E Jimenez; C L Shapiro; J Y Cho; S M Jhiang
Journal:  Breast Cancer Res Treat       Date:  2008-05-26       Impact factor: 4.872

9.  Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors.

Authors:  Séverine Trouttet-Masson; Samia Selmi-Ruby; Françoise Bernier-Valentin; Valérie Porra; Nicole Berger-Dutrieux; Myriam Decaussin; Jean-Louis Peix; Agnès Perrin; Claire Bournaud; Jacques Orgiazzi; Françoise Borson-Chazot; Brigitte Franc; Bernard Rousset
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

10.  Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.

Authors:  Vicki E Smith; Christopher J McCabe; Alice Fletcher; Martin L Read; Caitlin E M Thornton; Dean P Larner; Vikki L Poole; Katie Brookes; Hannah R Nieto; Mohammed Alshahrani; Rebecca J Thompson; Gareth G Lavery; Iñigo Landa; James A Fagin; Moray J Campbell; Kristien Boelaert; Andrew S Turnell
Journal:  Cancer Res       Date:  2019-10-31       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.